PDS Biotechnology Corporation (PDSB)

NASDAQ: PDSB · IEX Real-Time Price · USD
8.56
+1.84 (27.38%)
At close: May 26, 2023, 4:00 PM
8.80
+0.24 (2.80%)
After-hours: May 26, 2023, 7:59 PM EDT
27.38%
Market Cap 263.85M
Revenue (ttm) n/a
Net Income (ttm) -42.04M
Shares Out 30.82M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,172,480
Open 8.60
Previous Close 6.72
Day's Range 7.32 - 8.92
52-Week Range 2.89 - 13.65
Beta 1.87
Analysts Strong Buy
Price Target 18.25 (+113.2%)
Earnings Date May 15, 2023

About PDSB

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treat... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Frank K. Bedu-Addo Ph.D.
Employees 26
Stock Exchange NASDAQ
Ticker Symbol PDSB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is $18.25, which is an increase of 113.20% from the latest price.

Price Target
$18.25
(113.20% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients

Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1% A disease control ...

4 days ago - GlobeNewsWire

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023 Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023

1 week ago - GlobeNewsWire

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE NEWSWI...

2 weeks ago - GlobeNewsWire

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for ...

3 weeks ago - GlobeNewsWire

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

FLORHAM PARK, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies fo...

1 month ago - GlobeNewsWire

PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023

FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies fo...

1 month ago - GlobeNewsWire

PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023

PDS Biotech prepares to advance PDS0101 into a Phase 3 registrational clinical trial – VERSATILE-003 – in HPV16-positive recurrent and/or metastatic head and neck cancer in 2023 PDS Biotech prepares t...

2 months ago - GlobeNewsWire

PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023

Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, registrational trial in recurrent/metastatic HPV16-positive head and neck cancer Company has completed Phase 3 manufa...

2 months ago - GlobeNewsWire

PDS Biotech to Participate in Cantor's Future of Oncology Virtual Symposium

FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies fo...

2 months ago - GlobeNewsWire

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results

FLORHAM PARK, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies fo...

2 months ago - GlobeNewsWire

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results

FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies fo...

2 months ago - GlobeNewsWire

PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor

Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancer Received guidance on registrational path for combination i...

3 months ago - GlobeNewsWire

PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™

Infectimune™ (R-DOTAP) nanoparticles significantly enhance cytokine-inducing, CD4 T cell responses compared to leading commercial adjuvants being used in approved vaccines Infectimune™ (R-DOTAP) nanop...

3 months ago - GlobeNewsWire

PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses

Infectimune™ induced neutralizing antibody and robust T cell responses completely protecting animals against sickness after lethal challenge with live SARS-CoV-2 or influenza viruses Infectimune™ indu...

3 months ago - GlobeNewsWire

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress

Abstract, titled “HPV16-specific CD4 and CD8 T cell activation and functionality in patients receiving combination PDS0101 immunotherapy,” highlights data generated from VERSATILE-002 Phase 2 study Ab...

4 months ago - GlobeNewsWire

PDS Biotech Announces Participation in the Channelchek Takeaway Series

FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for...

4 months ago - GlobeNewsWire

PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference

FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for...

4 months ago - GlobeNewsWire

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform

5 months ago - GlobeNewsWire

PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months

Median OS of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive cancer patients in National Cancer Institute-led Phase 2 clinical trial of PDS0101 triple combination Median OS of 21 ...

5 months ago - GlobeNewsWire

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

VERSATILE-002 Phase 2 study investigating PDS0101 in combination with Merck's KEYTRUDA® (pembrolizumab) in both checkpoint inhibitor refractory and checkpoint inhibitor naïve patients VERSATILE-002 Ph...

5 months ago - GlobeNewsWire

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Frank Bedu-Addo, CEO PDS Biotechnology Corporation

NEW YORK, NY / ACCESSWIRE / December 5, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issu...

6 months ago - Accesswire

PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress

Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted immunotherapies for solid tumors based on the Versamune® platform

6 months ago - GlobeNewsWire

PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update

FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for...

7 months ago - GlobeNewsWire

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results

FLORHAM PARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for...

7 months ago - GlobeNewsWire

PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow up of 16 months 66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow up...

8 months ago - GlobeNewsWire